STOCK TITAN

Larimar Therapeutics Inc - LRMR STOCK NEWS

Welcome to our dedicated news page for Larimar Therapeutics (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Larimar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Larimar Therapeutics's position in the market.

Rhea-AI Summary
Larimar Therapeutics, Inc. successfully closed a public offering of 19,736,842 shares of common stock, raising approximately $172.5 million. The proceeds will support the development of nomlabofusp (CTI-1601) and other pipeline candidates, as well as general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
Larimar Therapeutics, Inc. announces the pricing of its public offering, generating approximately $150.0 million. The company is focused on developing treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.84%
Tags
offering
-
Rhea-AI Summary
Larimar Therapeutics, Inc. initiates a public offering of common stock and pre-funded warrants to support the development of pipeline candidates and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.84%
Tags
offering
Rhea-AI Summary
Larimar Therapeutics, Inc. announces positive Phase 2 data for nomlabofusp in Friedreich’s ataxia patients. The drug showed dose-dependent increases in frataxin levels in skin and buccal cells, with generally well-tolerated subcutaneous injections. The company plans an Open Label Extension study and aims for accelerated FDA approval by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
clinical trial
-
Rhea-AI Summary
Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported the completion of the full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial. The trial demonstrated no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups. Top-line safety, pharmacokinetic, and frataxin data from Phase 2 are now expected in Q1 2024, with initiation of open label extension (OLE) trial on track for Q1 2024. Larimar also reported $95.6 million in cash, cash equivalents, and marketable securities as of September 30, 2023, providing projected cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
earnings
-
Rhea-AI Summary
Larimar Therapeutics, Inc. will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York from November 6-7, 2023. The fireside chat will take place on November 7, 2023, from 1:10 - 1:40 PM ET. A replay of the chat will be available on Larimar's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences
Rhea-AI Summary
Larimar Therapeutics appoints Jeffrey W. Sherman, M.D., F.A.C.P. to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
management
-
Rhea-AI Summary
Larimar Therapeutics to participate in panel discussion and investor meetings at Citi BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
-
Rhea-AI Summary
Larimar Therapeutics has received FDA clearance to initiate the 50 mg cohort in the Phase 2 trial for Friedreich's ataxia (FA) and the open-label extension (OLE) trial. Top-line data from the 50 mg cohort is expected in 1H 2024. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $104.2 million. Larimar reported a net loss of $8.4 million for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
clinical trial
Larimar Therapeutics Inc

Nasdaq:LRMR

LRMR Rankings

LRMR Stock Data

767.53M
23.33M
1.4%
77.37%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bala Cynwyd

About LRMR

larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.